In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren’s disease. Shots: 180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete.

As many good and longstanding friendships do, it all started with beer. If you trace the roots of the partnership between Kyowa Kirin North America and the La Jolla Institute for Immunology deep enough, you’ll find the remnant hulls of seeds planted by research scientists and fertilized by beer. It was the mid-1980s, when research […]

What makes palmoplantar pustulosis symptoms so difficult to treat? Based on its unique makeup, relief can be challenging to find. Listen up to learn: What makes neutrophils so crucial The off-target affects new treatments The next stage of developing treatment James Mackay, the CEO of Aristea Therapeutics, shares his work researching inflammatory skin conditions and […]